AEZS Share Price

Open 2.75 Change Price %
High 2.75 1 Day -0.15 -5.56
Low 2.50 1 Week -0.35 -12.07
Close 2.55 1 Month -1.55 -37.80
Volume 205488 1 Year -0.51 -16.67
52 Week High 5.59
52 Week Low 2.35
AEZS Important Levels
Resistance 2 2.78
Resistance 1 2.69
Pivot 2.60
Support 1 2.41
Support 2 2.32
NASDAQ USA Most Active Stocks
ASTI 0.01 0.00%
QCOM 54.88 -12.72%
QCOM 54.88 -12.72%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
NASDAQ USA Top Gainers Stocks
EDMC 0.02 100.00%
CPSL 0.10 66.67%
LOCM 0.09 50.00%
ACFN 0.30 30.43%
LTRE 2.85 29.55%
WRES 0.09 28.57%
QKLS 0.14 27.27%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
QTWW 0.08 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%

AEterna Zentaris Inc. (NASDAQ: AEZS)

AEZS Technical Analysis 5
As on 23rd Jan 2017 AEZS Share Price closed @ 2.55 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 3.54 & Strong Sell for SHORT-TERM with Stoploss of 3.40 we also expect STOCK to react on Following IMPORTANT LEVELS.
AEZS Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
AEZS Other Details
Segment EQ
Market Capital 58779412.00
Sector Healthcare
Industry Biotechnology
Offical website
AEZS Address
1405 du Parc-Technologique Boulevard
Quebec City, QC G1P 4P5
Phone: 418-652-8525
Fax: 418-948-9191
Interactive Technical Analysis Chart AEterna Zentaris Inc. ( AEZS NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from
Your Comments and Response on AEterna Zentaris Inc.
AEZS Business Profile
Aeterna Zentaris Inc., incorporated on September 12, 1990, is a late-stage drug development company specialized in oncology and endocrine therapy. The Company’s pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. The development priorities in oncology are the completion of Phase 3 trials with perifosine in colorectal cancer (CRC) and in multiple myeloma (MM), as well as the further advancement of AEZS-108, for which it has completed a Phase 2 trial in advanced endometrial and advanced ovarian cancer. Its pipeline also encompasses other earlier-stage programs in oncology. AEZS-112, which is an oral anticancer agent, which includes three mechanisms of action (tubulin, topoisomerase II and angiogenesis inhibition) has completed a Phase 1 trial in advanced solid tumors and lymphoma. As of December 31, 2011, the Company had three wholly owned direct and indirect subsidiaries, Aeterna Zentaris GmbH (AEZS Germany), Zentaris IVF GmbH, a direct wholly owned subsidiary of AEZS Germany, and Aeterna Zentaris, Inc. In addition, several anti-cancer candidates, such as AEZS-120, a live recombinant oral tumor vaccine candidate, as well as its phosphoinositide 3-kinase (PI3K)/Erk inhibitors AEZS-129, AEZS-131, AEZS-132 and their respective follow-up compounds are in preclinical development. The Company’s program in endocrinology, a Phase 3 trial under a Special Protocol Assessment (SPA) obtained from the United States Food and Drug Administration (the FDA) with AEZS-130 as an oral diagnostic test for adult growth hormone deficiency (AGHD), has been completed. AEZS-130 is in a Phase 2A trial for the treatment of cancer cachexia. The Company’s LHRH Antagonists include Cetrorelix and Ozarelix, and its Immunotherapy / Vaccines consists of AEZS-120. Tumor targeting cytotoxic conjugates and cytotoxics consists of AEZS-137 (Disorazol Z)/AEZS-125(LHRH-DisorazolZ).